INOVIO Pharmaceuticals

INOVIO Pharmaceuticals INOVIO Pharmaceuticals, Inc.

INOVIO Pharmaceuticals Official page
We're trailblazers in the DNA medicine field, working to develop next-generation medicines to fight HPV-related disease, cancer and infectious disease. (INOVIO) is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and HPV-associated diseases. ​

IN

OVIO’s DNA medicines platform and proprietary smart device can target virtually any DNA sequence. With 15 clinical programs currently in development, INOVIO has the potential to save and protect lives worldwide and power a new decade of DNA medicines. ​

For more information, visit www.inovio.com.

Pleased to share that INOVIO management will be participating in several upcoming investor conferences, featuring webcas...
09/02/2026

Pleased to share that INOVIO management will be participating in several upcoming investor conferences, featuring webcast presentations and one-on-one investor meetings. Details are available on INOVIO’s events page: https://bit.ly/INO_Events

At our second quarter 2026 financial results call, CEO Dr. Jacqueline Shea highlighted important regulatory progress and...
08/13/2026

At our second quarter 2026 financial results call, CEO Dr. Jacqueline Shea highlighted important regulatory progress and commercial preparations for lead candidate INO-3107 as the company works towards its October target PDUFA date. To hear more on this and other corporate highlights, you can listen to the webcast replay here: https://bit.ly/INO2Q26

INOVIO reports financial results and operational highlights for the second quarter of 2026 – read more here: https://bit...
08/12/2026

INOVIO reports financial results and operational highlights for the second quarter of 2026 – read more here: https://bit.ly/45XwPFa

DYK that HPV causes 60-70% of all throat cancer? And that HPV-positive throat cancer is the most commonly diagnosed HPV-...
07/27/2026

DYK that HPV causes 60-70% of all throat cancer? And that HPV-positive throat cancer is the most commonly diagnosed HPV-related cancer in the US? With cases on the rise and few treatment options for patients with advanced disease, is researching how to leverage the T cell-generating power of DNA medicine in combination with a PD-1 checkpoint inhibitor to change the treatment paradigm for this HPV-related cancer.

On   we stand with the patients, families and caregivers whose lives have been impacted by Glioblastoma - the most commo...
07/16/2026

On we stand with the patients, families and caregivers whose lives have been impacted by Glioblastoma - the most common and deadly type of brain cancer. Supporting a critical need for new, effective treatments, is forging innovative partnerships to advance promising DNA medicine candidates targeting GBM – read more here: https://bit.ly/4l8DvHr

National Brain Tumor Society

DYK that   is caused by strains 6 & 11 of the human papillomavirus (HPV)? So today – 6/11 – we’re spreading awareness ab...
06/11/2026

DYK that is caused by strains 6 & 11 of the human papillomavirus (HPV)? So today – 6/11 – we’re spreading awareness about this debilitating rare disease and the urgent need for treatment options that can help every patient reduce their need for surgery. is proud to support the Recurrent Respiratory Papillomatosis Foundation in their efforts to amplify patient voices - because every surgery matters, every patient matters, and every patient deserves a treatment that works for them.

See you at   2026! INOVIO will be there to highlight promising research on rare disease protein replacement therapeutics...
06/08/2026

See you at 2026! INOVIO will be there to highlight promising research on rare disease protein replacement therapeutics and the transformational potential of our next-gen DNA medicine technology.

INOVIO is pleased to be participating in the upcoming 2026 Jefferies Global Healthcare Conference, where we’ll be discus...
05/28/2026

INOVIO is pleased to be participating in the upcoming 2026 Jefferies Global Healthcare Conference, where we’ll be discussing progress with lead candidate INO-3107 for and other highlights from our DNA medicine pipeline. Webcast available here: https://bit.ly/43Bk7e2

INOVIO is pleased to be at   this week to share additional data demonstrating how lead candidate INO-3107 for   elicits ...
05/27/2026

INOVIO is pleased to be at this week to share additional data demonstrating how lead candidate INO-3107 for elicits a targeted immune response that is associated with improved clinical outcomes for patients. Read the abstract here: https://bit.ly/3PvCMop

Address

660 W. Germantown Pike, Suite 110
Plymouth Meeting, PA
19462

Alerts

Be the first to know and let us send you an email when INOVIO Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to INOVIO Pharmaceuticals:

Shortcuts

Share